Slide 1: Stock exchange filing cover letter
06.11.2023 To, National Stock Exchange of India Limited BSE Limited “Exchange Plaza”, Floor- 25, P J Tower, Bandra-Kurla Complex, Dalal Street, Bandra (East) Mumbai 400 051 Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Earnings Presentation for Un-Audited Financial Results – Q2
Slide 2: Q2FY24 Earnings Presentation
Epigral Limited (formerly known as Meghmani Finechem Limited) Q2FY24 Earnings Presentation
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Epigral Limited (the “Company”) solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form
Slide 4: Company Overview
Company Overview Founded: 2007 30% 22% 5 Year Revenue CAGR (FY23) 5 Year EBITDA CAGR (FY23) Employees: 900+ 0.8x 32% Debt to Equity (FY23) ROCE (FY23) Capacity: Chlor-Alkali# – 421 KTPA Derivatives# – 190 KTPA Revenue from operations (₹ Cr) 2188 Certified: 1551 Responsible Care Certificate 710 829 6
Slide 5: Our Journey
Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) Commissioned 1st Increased capacity to Commissioned Commissioned incorporated Plant • Caustic Potash – • Chloromethanes – • Caustic Soda – 167 21 KTPA 50 KTPA • Caustic Soda – 119 KTPA KTPA • CPP – 60 MW Converted all Announced Ca
Slide 6: Q2FY24 - Key Highlights
Q2FY24 - Key Highlights Q2FY24 Operational Highlights: o YoY volume grew by 21% and QoQ grew by 12%. Majorly growth is coming from Derivatives & Specialty segment and partially from Chlor-Alkali business o Capacity utilization stood at 77% in Q2FY24 vs 71% in Q1FY24 o Realizations of all the product
Slide 7: Q2FY24 - Key Highlights: H1FY24 Strategic Highlights
Q2FY24 - Key Highlights H1FY24 Strategic Highlights: o Capex / Expansions o Epigral announced to enter into CPVC Compound with a capacity of 35,000 TPA. This expansion is expected to get commission in Q4FY24 o Epigral commissioned 18.34 MW Wind Solar Hybrid Power Plant in Q1FY24 o Expansion of CPVC
Slide 8: CMD Message
CMD Message “We witnessed sales volume growth both on YoY and QoQ basis. This led to 5% revenue growth and 20% PAT growth in the sequential quarter, despite a drop in realizations. Our capex commissioned last year contributed to this volume growth even in this tough business environment. We have bee
Slide 9: Q2FY24 Financial Highlights
Q2FY24 Financial Highlights Revenue – YoY Growth: -14% EBIDTA – YoY Growth: -50% PAT – YoY Growth: -58% 556 32% 478 16% 455 180 21% 23% 92 108 95 8% 7% 38 32 Q2FY23 Q1FY24 Q2FY24 Q2FY23 Q1FY24 Q2FY24 Q2FY23 Q1FY24 Q2FY24 ₹ Cr Margin -%
Slide 10: H1FY24 Financial Highlights
H1FY24 Financial Highlights Revenue EBIDTA PAT 1,088 34% 18% 933 368 22% 199 7% 203 70 H1FY23 H1FY24 H1FY23 H1FY24 H1FY23 H1FY24 ₹ Cr Margin %
Slide 11: Key ratios
Key ratios ROCE (%) ROE (%) Net Debt/EBITDA (x) 25% 21% 1.8 29% 1.5 22% H1FY23 H1FY24 H1FY23 H1FY24 H1FY23 H1FY24 *TTM EBIT, PAT and EBITDA are considered for above ratios **Capital employed in ROCE includes Capital Work in Progress
Slide 12: Revenue Transition towards Derivatives & Specialty Chemicals
Revenue Transition towards Derivatives & Specialty Chemicals 71% 69% 62% 62% 54% 46% 38% 38% 29% 31% Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 - Chlor-Alkali - Derivatives & Specialty Chemical
Slide 13: Project Update as on 30th September 2023
Project Update as on 30th September 2023 Capex Spends - ₹ Cr Expected % of project Product Capacity Commissioning completed Date Chlorotoluene & 145 - Q4FY24 80% its value chain 456 CPVC Resin 416 45 KTPA Q4FY24 85% (Additional) CPVC 225 35 KTPA Q4FY24 40% Compound FY2022 FY2023 FY2024E Estimated ca
Slide 14: Focused on ESG
Focused on ESG ENVIRONMENT o Focused on using best technology to manage critical resources, to moderate the consumption of energy and natural resources and drive operations efficiently o Focus is to manufacture more from less, basis for environment responsibility o Entered in JV to set up 18.34 MW W
Slide 15: Income Statement
Income Statement Particulars (₹ Cr) Q2FY24 Q2FY23 YoY % Change Q1FY24 QoQ % Change Total Revenue 479 557 -14% 456 5% Gross Profit 176 246 -28% 163 8% Gross Margin (%) 37% 44% 36% EBITDA 108 180 -40% 95 13% EBITDA Margin (%) 23% 32% 21% Depreciation 32 26 21% 31 2% Finance Cost 21 14 48% 18 16% PBT 5
Slide 16: Historic Income Statement
Historic Income Statement Particulars (₹ Cr) FY19 FY20 FY21 FY22 FY23 Total Revenue 720 613 831 1,555 2,196 Gross Profit 431 300 407 716 951 Gross Margin (%) 61% 49% 49% 46% 43% EBITDA 312 194 261 509 689 EBITDA Margin (%) 44% 32% 32% 33% 31% Depreciation 54 44 74 86 109 Finance Cost 25 11 29 44 66
Slide 17: Historic Balance Sheet
Historic Balance Sheet Assets (₹ Cr) FY22 FY23 H1FY24 Liabilities (₹ Cr) FY22 FY23 H1FY24 Fixed Assets 1,657 1,962 2,156 Share Capital 42 42 42 Financial Assets 8 28 28 Reserves & Surplus 684 1,028 1,087 Other Non-current Assets 11 23 26 Long-Term Borrowings 557 435 432 Inventories 154 212 197 Redee
Slide 18: About Epigral and contact details
Epigral Ltd (formerly known as Meghmani Finechem Ltd), incorporated For further information in 2007, is a leading integrated manufacturer of chemicals in India. The company has state of the art manufacturing facilities in Gujarat, Dahej – Please log on to website - www.epigral.com a leading PCPIR re